Marshall Wace’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Marshall Wace’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-249,715	Closed	-$12M	–	2132
2020 Q1	$12M	Buy	249,715 +223,380	+848%	+$10.4M	0.12%	180
2019 Q4	$1.24M	Buy	+26,335	New	+$1.16M	0.01%	932
2019 Q2	–	Sell	-10,225	Closed	-$229K	–	2060
2019 Q1	$229K	Buy	+10,225	New	+$220K	﹤0.01%	1310

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Marshall Wace's RARX Position: Q2 2020 in Review

Marshall Wace sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 249,715 shares — an estimated $12M sold.

Marshall Wace first reported a position in RARX in Q1 2019 and held it in 3 quarters. The position peaked at $12M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Marshall Wace reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Marshall Wace sold 249,715 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $12M.
Marshall Wace first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 3 quarters.
Marshall Wace's Ra Pharmaceuticals, Inc. Common Stock position peaked at $12M in Q1 2020.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Marshall Wace's 13F filing for Q2 2020, filed 13 Aug 2020.